Three-year study confirms TREMFYA delivers sustained remission for ulcerative colitis patients STOCKHOLM: Johnson & Johnson has released new long-term findings showing that TREMFYA® (guselkumab) provides durable disease control for adults with moderate to severe ulcerative colitis for up to three years. The data were obtained from the QUASAR long-term extension study and presented at the European Crohn’s and Colitis Organisation (ECCO) 2026 conference. Strong remission rates …

Three-year study confirms TREMFYA delivers sustained remission for ulcerative colitis patients #TREMFYA #UlcerativeColitis #GutHealth #IBD #ChronsDisease

Daytime scene at an empty, underground subway platform in a large city, facing across the tracks, and across the opposite platform, at a subway train going the other direction; the shiny, silver train has boarded and the doors have closed; a lighted sign above the window reads "R Broadway Local", which indicates that this is a local train stopping at all the stops; the R is one of the most important lines in the City - going from Forest Hills, Queens to Bay Ridge, Brooklyn; there are no other people around, however in the window of the R train, there is a passenger who looks to be asleep; most of the cars on the R have very good climate control equipment; an LED advertising screen is promoting a drug called Tremfya; this is considered normal in this particular country.

New York photo of the day.
Manhattan.
18°F (-8° C), partly cloudy.
#NYC #City #Subway #Train #MTA #Midtown #BrooklynBound #R-LocalTrain #Tremfya

FDA Grants TREMFYA® Approval for Pediatric Psoriasis and Arthritis Treatment TREMFYA® is now FDA approved for the treatment of pediatric patients with plaque psoriasis and active psoriatic arthritis, offering new hope for children with these conditions.

FDA Grants TREMFYA® Approval for Pediatric Psoriasis and Arthritis Treatment #United_States #TREMFYA #pediatric_psoriasis #Horsham #Psoriatic_Arthritis

TREMFYA® Gains FDA Approval for Subcutaneous Induction in Ulcerative Colitis Treatment Johnson & Johnson's TREMFYA® becomes the first and only fully subcutaneous IL-23 inhibitor, now approved for adult ulcerative colitis treatment.

TREMFYA® Gains FDA Approval for Subcutaneous Induction in Ulcerative Colitis Treatment #United_States #Ulcerative_Colitis #TREMFYA #Horsham #guselkumab

Introducing Tremfya: A Unique Treatment for Moderate to Severe Crohn’s Disease Tremfya is the only IL-23p19 inhibitor providing both subcutaneous and intravenous treatments for moderate to severe Crohn's disease. It has shown significant effectiveness.

Introducing Tremfya: A Unique Treatment for Moderate to Severe Crohn’s Disease #Japan #Tokyo #Crohn's_Disease #TREMFYA #Janssen

Johnson & Johnson's TREMFYA® Demonstrates Efficacy in Psoriatic Arthritis Treatment Discover how Johnson & Johnson's TREMFYA® offers significant benefits in treating active psoriatic arthritis, showcasing remarkable results in the APEX study.

Johnson & Johnson's TREMFYA® Demonstrates Efficacy in Psoriatic Arthritis Treatment #United_States #New_Brunswick #TREMFYA #guselkumab #Psoriatic_Arthritis

MHRA approves guselkumab for Crohn’s disease and ulcerative colitis - PharmaTimes Regulator confirms safety and efficacy of new treatment option for patient

#gastroenterology #MHRA #guselkumab #Tremfya #jmj #janssen #Crohnsdisease #ulcerativecolitis #plaquepsoriasis #psoriaticarthritis #activeCrohnsdisease #Clinicalstudies #Crohnsdiseasepatients #guselkumabtreatment
pharmatimes.com/news/mhra-ap...

Tremfya® Maintains Long-Term Clinical and Endoscopic Remission in Ulcerative Colitis Patients Latest data from Johnson & Johnson highlights Tremfya®'s efficacy in maintaining long-term remission in ulcerative colitis patients over 92 weeks, showcasing promising clinical outcomes.

Tremfya® Maintains Long-Term Clinical and Endoscopic Remission in Ulcerative Colitis Patients #USA #San_Diego #Ulcerative_Colitis #Johnson_&_Johnson #TREMFYA

TREMFYA® Shows Promising Long-term Remission Rates in Ulcerative Colitis Patients New data from Johnson & Johnson reveal that TREMFYA® (guselkumab) maintains over 70% clinical remission in ulcerative colitis patients over two years, offering hope for better management.

TREMFYA® Shows Promising Long-term Remission Rates in Ulcerative Colitis Patients #United_States #San_Diego #Ulcerative_Colitis #Johnson_&_Johnson #TREMFYA

Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis - PMLiVE The inflammatory condition affects approximately 30% of psoriasis patients

#immunology #rheumatology #InnovativeMedicine #jointhealth #JohnsonandJohnson #JandJ #JnJ #Tremfya #guselkumab #psoriaticarthritis #PsA #APEXtrial #activePsA #IL23blocker #pathogenesis #inflammatorydiseases #CD64receptor #CD64receptorbinder #IL23inhibitor #IL23treatment
pmlive.com/pharma_news/...

New Study Reveals TREMFYA® as First-Choice Treatment for Psoriatic Arthritis Johnson & Johnson announces TREMFYA® as the first IL-23 inhibitor effective in reducing psoriatic arthritis symptoms and preventing damage.

New Study Reveals TREMFYA® as First-Choice Treatment for Psoriatic Arthritis #Johnson_&_Johnson #TREMFYA #Psoriatic_Arthritis

FDA Approves TREMFYA® for Treating Crohn's Disease with Flexible Induction Options TREMFYA® has received FDA approval as the first dual-action IL-23 inhibitor for adults with Crohn's disease, offering both subcutaneous and intravenous treatment options.

FDA Approves TREMFYA® for Treating Crohn's Disease with Flexible Induction Options #United_States #Crohn's_Disease #TREMFYA #Horsham #guselkumab

TREMFYA® Shows Promise as a New Ulcerative Colitis Treatment with Unique Induction Options Johnson & Johnson's latest data on TREMFYA® reveals potential dual induction treatment methods for ulcerative colitis patients, enhancing therapeutic options.

TREMFYA® Shows Promise as a New Ulcerative Colitis Treatment with Unique Induction Options #USA #Ulcerative_Colitis #Spring_House #TREMFYA #guselkumab

Johnson & Johnson Pursues FDA Approval for TREMFYA® to Treat Children Johnson & Johnson has filed applications to FDA for TREMFYA®, aiming to treat children with moderate-to-severe psoriasis and juvenile psoriatic arthritis.

Johnson & Johnson Pursues FDA Approval for TREMFYA® to Treat Children #United_States #Johnson_&_Johnson #Spring_House #TREMFYA #pediatric_psoriasis